The ‘electric vehicles’ of pharma, Illumina’s boondoggle, & a Theranos sentencing
Who gets dibs on in-demand medicines? Can you get a refund on an $8 billion buy? And what happens when sweetheart deals go bad?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. STAT’s Elaine Chen joins us to explain how the escalating demand for a potent diabetes drug is putting patients with obesity in a difficult situation. We also discuss a curious trend in biotech investing, the future of Illumina, and another sentencing in the Theranos saga.
